Atazanavir/cobicistat
Atazanavir/cobicistat, sold under the brand name Evotaz, is a fixed-dose combination antiretroviral medication used to treat and prevent HIV/AIDS. It contains atazanavir and cobicistat. Atazanavir is an HIV protease inhibitor and cobicistat is an inhibitor of cytochrome P450 (CYP) enzymes of the CYP3A family.
| Combination of | |
|---|---|
| Atazanavir | HIV protease inhibitor |
| Cobicistat | Cytochrome P450 (CYP3A) inhibitor |
| Clinical data | |
| Trade names | Evotaz |
| AHFS/Drugs.com | Professional Drug Facts |
| License data | |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| KEGG | |
Atazanavir/cobicistat was approved by the Food and Drug Administration (FDA) for medical use in United States in January 2015. It was approved for medical use in the European Union in July 2015.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.